Although most clinical evidence suggests that tamoxifen is particularly effective for ER-positive breast cancer because it acts by competitive inhibition of ER and estrogen-regulated genes, which slows tumor progression [26],[49], a 10% to 15% response rate has been reported in patients with ER-negative breast cancer [26]. This evidence concerns the gene ESR1 and neoplasm.